At some point there will be a rush to buy psychedelic stocks.
The trigger might be a research breakthrough, a blockbuster IPO, positive results in a clinical trial, the takeover of a small drug development company by one of the larger players, or even something completely unforeseen.
But the fact remains – at some point it will happen.
You see, the macro forces propelling this market are too powerful to resist.
The scientific evidence supporting psychedelic assisted therapies is too compelling, and the worldwide need for these treatments too great.
They really could augment or replace existing therapies for depression, anxiety, post traumatic stress disorder and addiction.
Even so, extreme efforts were made over the years to suppress this market’s progress, but they have ultimately failed.
In 1971, an international treaty was signed at the United Nations that effectively led to a global ban on psychoactive substances.
The severe legislation was designed both to halt the supply of psychedelics and to stigmatize them.
Today, even mentioning the word “psychedelic” in ordinary conversation can provoke a deeply negative response.
Yet this is just misplaced emotion based on outdated propaganda.
Those that have researched modern psychedelic assisted therapies will know of their potential to transform millions of lives.
Thankfully, in the last 50 years, a small number of dedicated scientists worked around the global ban and conducted sophisticated research into the physical and emotional effects of psychedelics in controlled research settings.
These pioneers were firm in the belief that the careful administration of psychedelic compounds could treat illness by unlocking some of the human brain’s most complex mechanisms.
It now looks like they were right.
The results of their studies and trials were consistently outstanding.
In spite of such a hostile environment, the forerunners of today’s psychedelic sector showed the potential benefit these substances could have in helping to treat many mental health conditions.
Thanks to their perseverance, important research into psychedelics has been embraced by the mainstream over the last few years.
October 2018 marked a pivotal moment in this movement.
The U.S. Food & Drug Administration awarded “Breakthrough Therapy Designation” to U.K. research group Compass Pathways. This allowed it to test the safety and effectiveness of psilocybin – the active ingredient in magic mushrooms – to combat treatment-resistant depression.
The floodgates were opened.
Endorsement from the FDA heralded a quantum leap forward for the expansion of the psychedelic sector.
Companies could now proceed with their research programs, safe in the knowledge that official blessing had become a precedent.
Thanks to their long-standing advocacy in support of psychedelic assisted therapies to treat mental health conditions, the founders of Numinus Wellness Inc. (TSX-V:NUMI) were among the first to recognize this fast-developing commercial opportunity.
Crucially, they also spotted where the battle for success would first be lost or won – The recruitment of a team of skilled researchers capable of designing and developing the next generation of psychedelic assisted therapies.
Success in the psychedelic sector will be decided by the brightest minds
One of the most appealing aspects about the psychedelic space is that it will likely be a highly concentrated market on the supply side.
First-class research is already at the heart of the sector, and there aren’t many experts in the field.
The prolonged global ban has restricted the number of active specialists available today.
Even though the walls of prohibition are coming down, and we are witnessing the birth of what Canaccord Genuity believes could become a US$100 billion market, that legacy presents a very real near-term challenge.
In fact, it is so pressing, that if companies hoping to break into the market haven’t already secured their research personnel then it is probably already too late.
A bit like the NFL draft, the top talent got picked early.
Dr Wood is a rock star in the substance use research and drug policy world, whose work is recognized the world over.
He founded or created a host of entities that contributed to medical and drug policy reforms including the International Centre for Science in Drug Policy. He’s been routinely quoted by international news organizations (e.g. CNN), and has co-authored more than 400 scientific papers in the world’s top medical journals.
But it is his ongoing role as a professor of medicine at the University of British Columbia and his leadership role at the British Columbia Centre on Substance Use (BCCSU) that really provides Numinus (TSX-V:NUMI) with a crucial competitive edge.
Dr Wood’s lab at the University of British Colombia (UBC) and St. Paul’s hospital has a longstanding track record of taking on challenging projects and overcoming obstacles. Not only does it deliver the highest quality research, but it also has a track record of implementing this knowledge in the real world.
Roughly a decade ago, Dr. Wood founded the Stop the Violence BC Coalition, which was a key driving force in the move to legalize adult cannabis use in Canada .
Alongside this, Dr Wood and his team have also been heavily involved in a host of addiction prevention and treatment initiatives including being a principal investigator of the evaluation of North America’s first medically supervised safer injecting facility.
Dr. Wood’s research was widely cited in the unanimous Canadian Federal Supreme Court decision that has allowed these interventions to become commonplace in Canada.
And that is not to mention his research on treating HIV infection among heroin users helped shape British Columbia’s HIV prevention and treatment strategy that has seen HIV/AIDS rates plummet by approximately 90%.
He also led the creation of new national guidelines and standards for addictive disorders.
As Professor of Medicine at the UBC, Wood helps lead the university’s response to substance use and related mental health challenges through a federally funded Tier 1 Canada Research Chair. These positions are reserved only for outstanding researchers, acknowledged by peers in their disciplines as world leaders.
So, when Dr Wood and his colleagues turned their attention towards psychedelics as a treatment option for addictions in April 2017, they quickly secured official backing.
Three years later, and they have made significant progress in a host of research to evaluate using psychedelic compounds to develop health-focussed, evidence-based treatment methods for different addictive disorders and post traumatic stress disorder.
And that’s not all.
The scope of Dr Wood and his team’s work expands to the study of the other therapeutic benefits psychedelics might hold.
Now, armed with this knowledge base and practical experience, Dr Wood is ready to oversee the deployment of his life’s mission outside of the laboratory and into the real world.
Set up to do BIG things- Numinus Wellness Inc. (TSX-V:NUMI)
With such strong backing, Numinus (TSX-V:NUMI) is perfectly positioned to ride the crest of the psychedelic wave.
In the words of the firm’s Chief Executive Payton Nyquvest, the company has been set up “to do BIG things.”
And it has already started to deliver on this promise.
Only last week, Health Canada issued a research amendment to Numinus’ (TSX-V:NUMI) Dealer’s License making it the first publicly traded company permitted to produce and extract psilocybin from mushrooms.
For a company of Numinus’ (TSX-V:NUMI) size, this achievement is momentous.
Not only does it vindicate the firm’s research pedigree, but it also signals the company’s ability to execute its strategy.
No wonder other prominent experts are flocking to join Numinus’ (TSX-V:NUMI) ranks.
Dr. Gabor Maté, one of the leading trauma doctors in the world, joined the company’s clinical advisory team at the end of May.
Then, in early June, Dr Devon Christie became the firm’s medical director. A specialist in psychedelic-assisted therapies, she will oversee development of Numinus’ (TSX-V:NUMI) treatment methods in clinical settings.
More appointments are expected to follow. But it is already clear that the stars are aligning for this stock’s awesome potential.
Numinus (TSX-V:NUMI) dedicated 7,000sqft Health Canada licensed laboratory enables it to support cutting-edge research into psychedelic assisted therapies and therapies.
The plan then is to roll out ground-breaking treatments for mental health conditions across North America, through wholly-owned or partner clinics, once approval is received from regulators.
Considering that target patient populations number in the millions across the U.S. and Canada alone, the sheer scale of the opportunity becomes abundantly clear.
With the core of its impressive team in place, Numinus (TSX-V:NUMI) is now poised to deliver exceptional growth.
IMPORTANT NOTICE AND DISCLAIMER PAID ADVERTISEMENT.
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Numinus Wellness Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and thirty six thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
Changes in Share Trading and Price
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
No Offer to Sell or Buy Securities
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.
No Financial Advice
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
Forward Looking Statements
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
Indemnification/Release of Liability
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.
Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.
This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
Ben Turney does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney has been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.